The study orchestrated by Oshima, Takayama, Nakajima-Takagi, and colleagues deploys advanced single-cell ATAC-seq technology to map chromatin accessibility changes in hematopoietic stem and progenitor cells (HSPCs) isolated from patients with varying stages of MDS. These regulatory changes are crucial because chromatin accessibility directly influences transcription factor binding and gene expression, thus dictating cell fate and function. Previous studies had largely overlooked the dynamics of chromatin remodeling at the stem cell level in MDS, focusing instead on bulk populations of mature cells. This new angle sharpens the molecular resolution and provides insights into the earliest events driving disease onset and progression.

The authors found that as MDS evolves, there is a distinct and progressive alteration in chromatin accessibility profiles within stem cells. These alterations were not abrupt but manifested as a continuum of epigenetic reprogramming events, revealing that the disease process is marked by a gradual rewiring of gene regulatory networks. Notably, stem cells from MDS patients showed a diminished accessibility in genomic regions linked to hematopoietic differentiation, alongside enhanced accessibility in regions associated with inflammatory signaling and stress response pathways. This dual pattern suggests a pathological shift wherein stem cells progressively lose their normal differentiation potential while acquiring abnormal stress-adaptive traits that may promote clonal dominance and survival.

Central to the study’s findings is the identification of key transcription factor motifs whose binding sites were variably accessible along the disease trajectory. These motifs belong to regulatory players such as RUNX1, GATA2, and SPI1, all critical to hematopoietic stem cell maintenance and lineage commitment. The researchers demonstrated that the differential accessibility of these motifs correlates with transcriptional changes in corresponding target genes, highlighting an intricate epigenetic-transcriptional feedback loop. The disruption of this regulatory network likely contributes to the hematopoietic dysregulation seen in MDS, offering new candidate targets for precision medicine interventions.

Furthermore, the research delineates a clear distinction between early and advanced MDS based on chromatin features. Early MDS stem cells showed subtle yet distinct epigenomic alterations that may serve as early biomarkers of disease. In contrast, advanced-stage MDS cells exhibited widespread chromatin remodeling, culminating in global transcriptional chaos and loss of hematopoietic identity. This insight advances the field’s understanding of MDS heterogeneity and may guide risk stratification and prognosis in clinical settings.

Complementing the chromatin accessibility data, the study incorporates single-cell RNA sequencing to validate transcriptional outputs corresponding to epigenomic changes. This integrative approach strengthens the causal link between chromatin dynamics and gene expression programs that underlie disease phenotypes. The combined datasets also revealed unexpected activation of inflammatory signaling pathways within the stem cell compartment itself, reinforcing the emerging view that inflammation is not merely a secondary event but a driver of MDS pathogenesis.

Importantly, the team’s work underscores the plasticity and vulnerability of hematopoietic stem cells in the face of genetic and epigenetic insults. MDS mutations often affect epigenetic regulators, but the precise impact on chromatin architecture and how it disrupts normal hematopoiesis has remained unclear. By focusing on chromatin accessibility, the study offers a functional readout of how these mutations translate into altered regulatory landscapes, thereby connecting genotype to phenotype at a mechanistic level.

The implications of these findings are vast. Therapies that aim to restore normal chromatin accessibility or correct aberrant transcription factor binding patterns may hold promise in arresting or reversing MDS progression. The data also provide a framework for identifying patients at high risk of leukemic transformation by tracking epigenomic shifts in stem cells, enabling earlier and more effective therapeutic interventions. Moreover, this epigenetic roadmap can serve as a platform for screening drug candidates that modulate chromatin state or transcriptional machinery specifically in malignant stem cells.

While the study marks a significant leap forward, it also raises compelling questions for future research. How do specific mutations interact with the epigenomic environment to shape disease trajectory? Can these chromatin changes be modulated in vivo to restore normal hematopoiesis? And what role might the bone marrow niche and immune microenvironment play in reinforcing or mitigating these epigenetic alterations? Addressing these will be crucial to translating these mechanistic insights into effective therapies.

Interestingly, the progressive nature of chromatin remodeling unveiled here challenges the conventional notion of MDS as a static disorder. Instead, it should be viewed as a dynamic evolutionary process driven by iterative epigenetic and transcriptional changes. This conceptual shift underscores the importance of longitudinal monitoring of patients’ chromatin landscapes, potentially through minimally invasive assays in peripheral blood progenitors or circulating stem cells.

The study also illuminates the broader principle that chromatin accessibility profiling at single-cell resolution can unravel disease trajectories in complex clonal disorders beyond MDS. This methodological advance sets a precedent for dissecting epigenetic heterogeneity in other hematologic malignancies and solid tumors, fostering a more nuanced understanding of cancer evolution and resistance.

In summary, the research by Oshima et al. provides a captivating glimpse into the epigenetic underpinnings of myelodysplastic syndromes. By combining state-of-the-art single-cell techniques with rigorous computational analyses, the team paints a vivid picture of how stem cell chromatin landscapes progressively deteriorate, heralding disease onset and escalation. These findings not only deepen our biological understanding but also pave the way for novel diagnostic and therapeutic approaches aimed at intercepting MDS at its roots.

The meticulous work stands as a testament to the power of integrative genomics and epigenomics in unraveling the complex interplay between genetics, cell biology, and disease. As we move toward an era of precision medicine enriched with epigenetic insights, studies like this will be indispensable in crafting interventions that are both targeted and adaptable, fundamentally improving patient outcomes in MDS and potentially other malignancies derived from stem cell dysregulation.

Subject of Research: Chromatin accessibility and transcriptional changes in hematopoietic stem cells during progression of myelodysplastic syndrome.

Article Title: Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome.

Article References:
Oshima, M., Takayama, N., Nakajima-Takagi, Y. et al. Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome. Nat Commun 16, 10726 (2025). https://doi.org/10.1038/s41467-025-65753-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65753-5

This election marks a pivotal moment for Dr. Sekeres, recognizing his extensive contributions to hematology, particularly in the study and treatment of myelodysplastic syndromes and acute myeloid leukemia (AML) among older adults. His role at Sylvester involves directing an internationally acclaimed program that integrates clinical expertise with cutting-edge research in hematologic malignancies, emphasizing therapeutic innovation tailored to geriatric patient populations.

The American Society of Hematology stands at the forefront of scientific rigor and clinical excellence, advocating vigorously for patients affected by blood disorders. Dr. Sekeres expressed profound honor at joining the executive leadership, highlighting the society’s commitment to advancing the field through robust scientific inquiry, development of clinical guidelines, and education. His impending responsibilities will involve steering ASH’s strategic initiatives during a critical juncture where blood disease research is rapidly evolving.

Since joining ASH in 2002, Dr. Sekeres has been deeply involved in various leadership roles, cultivating comprehensive treatment guidelines targeted at older adults with AML, a demographic often underserved in clinical research. His chairmanship of the Older Adults with AML Treatment Guidelines Panel epitomizes his dedication to integrating evidence-based medicine with compassionate clinical care, addressing the unique challenges posed by age-related physiological changes and comorbidities.

Moreover, his prior leadership includes serving as chair of the Committee on Communications and founding editor-in-chief of ASH Clinical News, a widely read publication that has played an instrumental role in disseminating hematology research and clinical advancements to a broad professional audience. Under his editorial guidance, the publication enhanced its impact, fostering dialogue among clinicians and researchers while promoting accessibility to emerging findings.

The 2025 Executive Committee election also brought in other distinguished leaders, including Alison Loren, M.D., M.S.C.E., chief of the Division of Hematology/Oncology at the University of Pennsylvania, who will serve as vice president, and Adam Cuker, M.D., M.S., a professor of medicine at the same institution, who will serve as councillor. These appointments underscore a trend of fostering interdisciplinary collaboration and integrating diverse academic perspectives to propel hematology forward.

Dr. Belinda Avalos, the 2025 ASH President, emphasized the significance of this leadership team amid an era characterized by both remarkable scientific discoveries and challenges threatening the integrity of the biomedical research ecosystem. She acknowledged that Drs. Loren, Cuker, and Sekeres bring unparalleled expertise essential for navigating the complex landscape of basic science advancements and clinical translation, especially as precision medicine and immunotherapy continue reshaping cancer treatment paradigms.

The Sylvester Comprehensive Cancer Center, home to Dr. Sekeres’s research, is noted for its pioneering work in translational oncology and hematologic research. The center’s focus on integrating molecular genetics, epigenetics, and immunologic factors has contributed substantially to understanding the pathophysiology of AML and related disorders, facilitating the development of targeted agents and personalized therapeutic approaches.

Dr. Sekeres’s ascent to the ASH Executive Committee represents not only personal recognition but also an acknowledgment of the growing importance of geriatric hematology as a subspecialty. The complex interplay of aging biology, comorbid conditions, and hematopoietic dysfunction demands tailored treatment frameworks, an area where his leadership is poised to influence policy, research priorities, and clinical practice guidelines substantially.

As the field confronts emerging hematologic challenges—such as drug resistance mechanisms, clonal hematopoiesis, and the integration of novel immunotherapies—ASH’s governance, enriched by Dr. Sekeres’s expertise, is positioned to play a decisive role in guiding research funding, educational programs, and advocacy efforts that will ultimately improve patient outcomes worldwide.

For those interested in further developments from Sylvester’s research teams and Dr. Sekeres’s ongoing projects, updates and news are regularly posted on the InventUM blog and Sylvester’s official social media channel on platform X (@SylvesterCancer). These platforms provide insights into innovative therapies, clinical trials, and multidisciplinary collaborations aiming to advance hematologic oncology.

In summary, Dr. Mikkael Sekeres’s election to ASH’s Executive Committee is a testament to his exemplary leadership and scientific achievements in hematology. His tenure promises to strengthen the Society’s mission to improve the lives of patients with blood disorders through science-driven care, policy advocacy, and educational excellence during a transformative era in medical science.

Subject of Research: Hematology, focusing on myelodysplastic syndromes and acute myeloid leukemia in older adults.

Article Title: Dr. Mikkael Sekeres Elected to Executive Committee of the American Society of Hematology

News Publication Date: October 16, 2025

Web References:

• University of Miami Miller School of Medicine: https://umiamihealth.org/locations/sylvester-comprehensive-cancer-center
• ASH Annual Meeting 2025: https://www.hematology.org/meetings/annual-meeting
• InventUM blog: https://news.med.miami.edu/
• Sylvester on X: https://x.com/SylvesterCancer

Image Credits: Photo by Sylvester Comprehensive Cancer Center

Keywords: Hematology, Oncology, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Older Adults, American Society of Hematology, Clinical Guidelines, Blood Disorders, Translational Research, Cancer Therapy, Precision Medicine, Hematologic Malignancies

The announcement, made on April 26, recognizes Dr. Steidl’s exemplary contributions to understanding the pathogenesis of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), two hematologic malignancies with complex stem cell origins. His election to the AAP underscores his stature as a leader synthesizing basic molecular insights with translational strategies aimed at improving patient outcomes. According to the AAP, membership is conferred upon individuals who demonstrate exceptional physician-led scientific leadership and groundbreaking research accomplishments.

At the heart of Dr. Steidl’s research lies a profound investigation into the biology of hematopoietic stem cells that give rise to MDS and ultimately AML. His work, driven by robust NIH and private funding, delves into the molecular abnormalities within pre-leukemic stem cells — the precursors to malignant clones. By elucidating the cellular pathways and genetic alterations underpinning the transition from pre-leukemic to full leukemic states, Dr. Steidl has charted pathways that are critical for early intervention and targeted therapy development. This insight is shifting paradigms in hematologic oncology, moving from symptom management to molecularly precise disruption of disease progression.

Significantly, Dr. Steidl was among the first researchers to demonstrate the defective nature of hematopoietic stem cells in MDS, a disorder recognized as a precursor to AML. This conceptual breakthrough, published in high-impact journals such as Nature Medicine, revolutionized the understanding of how these diseases originate and evolve at the stem cell level, challenging previously accepted models. Through this work, he has laid the foundation for novel therapeutic agents currently undergoing clinical trials, aiming to eradicate the aberrant stem cell populations that drive disease perpetuation and relapse.

The translational arc of Dr. Steidl’s research is underscored by his receipt of the National Cancer Institute’s Outstanding Investigator Award in 2021 — a competitive grant that supports sustained, innovative research endeavors. This award, accompanied by a seven-year funding commitment of $7 million, enables his laboratory to probe deeper into the genetic and epigenetic mechanisms governing stem cell transformation. It also facilitates the development and testing of drug candidates designed to selectively target malignant stem cells without compromising normal hematopoiesis, a critical balance in preventing treatment-related toxicity.

In addition to his laboratory investigations, Dr. Steidl holds the Edward P. Evans Endowed Professorship for Myelodysplastic Syndromes and serves as interim director of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine. His leadership roles emphasize his commitment to fostering interdisciplinary collaboration and advancing regenerative approaches to hematologic disease. The Gottesman Institute represents a hub where stem cell biology, molecular genetics, and translational medicine converge to create innovative therapeutic strategies.

Dr. Steidl’s work is characterized by the seamless integration of cutting-edge genomic technologies, including single-cell RNA sequencing and CRISPR-Cas9 gene editing, with classical hematology. This combination allows his team to dissect the cellular heterogeneity within MDS and AML, identifying rare populations of cells that resist conventional chemotherapy and contribute to disease relapse. These findings have profound implications for the design of next-generation therapeutics capable of achieving long-term remission or cure.

Yaron Tomer, M.D., the Marilyn and Stanley M. Katz Dean at Einstein and chief academic officer at Montefiore Einstein, lauded Dr. Steidl’s induction into the AAP as a testament to his scientific rigor and translational impact. He highlighted Dr. Steidl as a physician-scientist whose research exemplifies how mechanistic studies at the molecular level can directly inform clinical practice. This bridge between bench and bedside is essential for addressing the unmet needs of patients afflicted by aggressive hematologic cancers.

More than 150 peer-reviewed publications bear Dr. Steidl’s name, illustrating the depth and breadth of his contributions to cancer biology. His research not only advances fundamental understanding but also influences clinical protocols, as several experimental therapies originating from his findings are in human trials. These trials evaluate compounds targeting aberrant survival pathways and stem cell self-renewal mechanisms, reflecting a new era of precision medicine in blood cancers.

The Montefiore Einstein Comprehensive Cancer Center, where Dr. Steidl is a deputy director, represents a model institution that merges scientific discovery with patient-centered care. NCI-designated since 1972, the center serves one of the nation’s most diverse populations, with a deliberate focus on reducing health disparities through inclusive research and community engagement. Dr. Steidl’s appointment to this leadership cadre reinforces the center’s commitment to excellence in cancer stem cell research.

Among the distinguished cohort of previous Albert Einstein College of Medicine faculty elected to the AAP are renowned physician-scientists who have made landmark contributions across various disciplines. The induction of Dr. Steidl continues this legacy of scientific achievement and highlights the institution’s role as a breeding ground for innovation in medical research.

Dr. Steidl expressed profound gratitude for the recognition, acknowledging the collaborative environment at Einstein, the inspiration derived from patients, and the support from colleagues and trainees. His statement reflects a dedication not only to advancing scientific frontiers but also to mentoring the next generation of physician-scientists who will carry forward the torch of translational research.

In sum, Dr. Ulrich Steidl’s election to the Association of American Physicians underscores his seminal role in uncovering the molecular drivers of MDS and AML, shaping new therapeutic landscapes, and exemplifying the integration of rigorous science with compassionate clinical care. His work heralds promising directions for the treatment of complex blood malignancies, emphasizing early detection and targeted intervention at the stem cell level. As the field evolves towards more personalized and effective therapies, Dr. Steidl’s discoveries continue to illuminate the path forward.

Subject of Research: Molecular and cellular mechanisms underlying myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with emphasis on the biology of pre-leukemic and leukemic stem cells.

Article Title: Ulrich Steidl, M.D., Ph.D., Joins Association of American Physicians for Pioneering Work in Blood Stem Cell Research

News Publication Date: April 26, 2024

Web References:

• Faculty profile: https://einsteinmed.edu/faculty/11118/ulrich-g-steidl
• Montefiore Einstein Comprehensive Cancer Center: https://montefioreeinstein.org/cancer
• Albert Einstein College of Medicine: https://einsteinmed.edu

References:

• Steidl U, et al. “Myelodysplastic syndromes arise from hematopoietic stem cells with molecular defects.” Nature Medicine. 2018. https://www.nature.com/articles/s41591-018-0267-4

Image Credits: Albert Einstein College of Medicine

Keywords: Stem cell research, Cancer research, Clinical research, Hematologic malignancies, Myelodysplastic syndromes, Acute myeloid leukemia, Translational research, NIH Outstanding Investigator Award, Molecular biology, Targeted therapy, Precision medicine